Summary
In a significant market movement during May 2023, PharmEnable was the subject of a vc funding. The transaction achieved a gross valuation of £6,000,000. Leading the round was MP Healthcare Venture Management, Wren Capital, Arrowfield Capital, Cambridge Enterprise, o2h Ventures, Heyford Trust, Jonathan Milner, Martlet Capital.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
MP Healthcare Venture Management
Lead Investor / Acquirer
Wren Capital
Lead Investor / Acquirer
Arrowfield Capital
Lead Investor / Acquirer
Cambridge Enterprise
Lead Investor / Acquirer
o2h Ventures
Lead Investor / Acquirer
Heyford Trust
Lead Investor / Acquirer
Jonathan Milner
Lead Investor / Acquirer
Martlet Capital
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Seed prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in